🇺🇸 FDA
Patent

US 11273182

Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

granted A61KA61K35/28A61K35/35

Quick answer

US patent 11273182 (Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease) held by Takeda Pharmaceutical Company Limited expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K35/28, A61K35/35, A61P, A61P1/00